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Multivariable prognostic models combine several 
characteristics to provide predictions for individual patients. 
Prognostic models can be applied in research and clinical 
practice, for instance to assist clinicians with decisions 
regarding treatment choices or informing patients and 
family members on prognosis (1). Before application in 
clinical practice, prognostic models should be validated 
to judge their generalizability. Although guidelines have 
been proposed to improve development and reporting of 
prognostic models, a majority of the published models is 
not thoroughly validated (1,2). In this viewpoint, we focus 
on design and analysis of validation studies for prognostic 
models. For illustration, we consider the validation of the 
International Mission for Prognosis and Analysis of Clinical 
Trials in Traumatic Brain Injury (IMPACT) prognostic 
models for patients with moderate and severe traumatic 
brain injury. These models combine clinical, radiological 
and laboratory admission characteristics to predict risk of 
mortality and unfavorable outcome (3). A second example 
is on computed tomography (CT) decision rules in patients 
with minor head injury (4).
Model development
Development of a prognostic model needs to consider 
various steps, such as the specification and coding of 
predictors for the model, and how to estimate the model 
parameters (5). Regression modeling is the most common 
approach, while machine learning techniques are 
gaining interest. Both regression and machine learning 
methods provide predictions for individual patients. It is 
important to evaluate the quality of the predictions for 
the derivation cohort (internal validation) as well as for 
new settings that may differ from the derivation cohort 
(external validation) (5,6).
Internal validation
Apparent val idation implies assessment of  model 
performance directly in the derivation cohort. This approach 
yields an optimistic estimate of model performance, because 
the regression coefficients are optimized for the derivation 
cohort (5). Split-sample validation entails random 
splitting of the derivation cohort into a development 
and validation sample. This is a standard but inefficient 
procedure, and is therefore not recommended (6). 
Cross-validation and bootstrap resampling are more 
reliable and desirable methods for internal validation. 
Cross-validation comprises model development on a part 
of the derivation cohort, and validation on the rest of the 
sample. This process is repeated until all patients have 
been used for model validation, and model performance is 
estimated over all validations (5). A 10-fold cross-validation 
uses 90% of the derivation sample for development with 
validation at 10%; repeated 10 times. Bootstrap resampling 
indicates drawing random samples with replacement from 
the derivation cohort, with sample size equal to that of the 
original cohort. A model is constructed in the bootstrap 
sample, and its performance is evaluated both in the 
bootstrap sample and the original cohort. The difference 
indicates the optimism in performance (5). This optimism 
is subtracted from the apparent performance to indicate the 
expected model performance for future patients similar to 
the derivation cohort. At least 100 samples should be drawn 
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to obtain stable estimates.
External validation
External validation relates to the generalizability and 
transportability of the prognostic model to another 
population (1,5). For example, the IMPACT models 
were validated in the Corticosteroid Randomisation after 
Significant Head Injury (CRASH) trial—an independent 
and more recent cohort (3). An elegant variant of cross-
validation can also be applied if data from multiple studies 
are analyzed: validation by leaving out all of the included 
studies once (3,7).
Performance measures
The classic measures to express model performance are 
discrimination and calibration. Discrimination refers to 
the ability of the prognostic model to distinguish between 
high and low risk patients, and is commonly quantified 
with the concordance statistic (C-statistic, equal to the area 
under the receiver operating characteristic curve, AUC). 
At internal validation, optimism in the C-statistic of the 
IMPACT models was minimal according to a bootstrap 
resampling procedure. This is explained by the large sample 
size (>5,000 patients in all analyses). At cross-validation 
by study, C-statistics ranged between 0.66 and 0.87, 
with slightly better performance with increasing model 
complexity. At validation in the CRASH trial, the C-statistics 
for the IMPACT core and extended models ranged from 
0.78 to 0.83 (3). Note that the discriminative ability of a 
model at external validation is influenced by differences 
in case-mix between the derivation and validation cohort. 
Discriminating high from low risk is more feasible in a 
heterogeneous population (e.g., an observational study) than 
in a homogeneous population (e.g., a randomized trial). 
Indeed, higher C-statistics were found when validating the 
IMPACT models in less selected cohorts rather than in a 
randomized controlled trial with strict inclusion criteria (8). 
 Calibration indicates the agreement between observed 
outcomes and predicted probabilities. Calibration may be 
assessed graphically in a calibration graph (Figure 1A,B). 
Ideally, we observe a 45 degree line with calibration slope 
1 and intercept 0. Calibration is less relevant at internal 
validation, because any model provides on average correct 
predictions for the derivation cohort. At external validation, 
the IMPACT models showed some miscalibration, with 
systematic underestimation of the risk for mortality and 
unfavorable outcome (Figure 1A,B) (3). Such systematic 
miscalibration may be attributed to differences in 
predictors that were not included in the proposed model, 
e.g., differences in treatment. In the current literature on 
prognostic models, the importance of model calibration is 
often undervalued. Adequate model calibration is however 
crucial for adequately informing patients about their risks, 
and for decision support (9).
Decision support
Some prognostic models explicitly aim to support clinical 
decision making. For these models, an additional decision-
analytic evaluation is required, beyond discrimination and 
calibration. An example of such an evaluation is provided for 
the validation of CT decision rules in minor head injury (4). 
These rules are used to identify patients with minor head 
injury at risk of intracranial complications who need a CT. 
In this decision problem, the need to identify patients with 
a clinically relevant intracranial abnormality (true positives) 
is weighed against the wish to avoid unnecessary CTs (false 
positives). A decision-analytic measure that can be used to 
express this balance is net benefit (NB). NB is calculated 
as a weighted sum of true and false positive classification: 
(true positives – weight × false positives) / total number 
of patients (4,5,10). The weight is defined clinically by 
balancing the relative importance of the benefits and harms. 
To facilitate interpretation of NB and judge clinical utility 
of the model, a ‘decision curve’ can be plotted with a range 
of risk thresholds. The NB of a CT decision rule needs to 
be better than the reference strategies “no scanning” and 
“scanning all patients” (10).
Conclusions
Validation of prognostic models is a crucial step before 
we start implementation in clinical practice. Models 
should be internally and especially externally validated to 
obtain reliable estimates of model performance, including 
assessments of discrimination and calibration. Decision-
analytic evaluation is important to identify models that aim 
to improve clinical decision making. Finally, variation in 
model performance is commonly observed across different 
settings when a prognostic model is externally validated 
extensively. Therefore, validated prognostic models should 
be applied in addition to clinical experience and only if the 
model is expected to be applicable to the specific setting and 
patient.
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Figure 1 Calibration plots for the (A) International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury 
(IMPACT) core model (including age, motor score and pupillary activity) and (B) IMPACT computed tomography (CT) model (extending 
the core model with CT characteristics and history of hypoxia and hypotension). Mortality and unfavorable outcome were evaluated in 
the Corticosteroid Randomisation after Significant Head Injury (CRASH) trial. The distribution of predicted probabilities is shown at the 
bottom of the graphs, stratified by outcome. Reprinted with permission from Steyerberg et al. (3).
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